Deutsche, Needham talk eteplirsen as Sarepta falls by nearly two-thirds

Deutsche's Robyn Karnauskas weighs in on what, quite frankly, has been a nightmarish day for Sarepta Therapeutics (SRPT -63.4%).

Karnauskas is now modeling a 2016 launch for eteplirsen. "Every 1 year delay impacts the DCF by $10/share," the analyst notes.

Needham's Chad Messer is also out with some commentary, saying that while he "continues to believe in the efficacy and safety of eteplirsen, [he is] downgrading [the] shares to Hold [after losing] visibility to the regulatory hurdles for approval."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs